Home / Resources / Videos / AACE 2018 / Dace Trence Part 5, Diabetes and Cardiovascular Combo Therapy

Dace Trence Part 5, Diabetes and Cardiovascular Combo Therapy

In part 5, the conclusion of this Exclusive Interview, Dace Trence talks with Diabetes in Control during the AACE 2018 convention in Boston about diabetes and cardiovascular combo therapy, and how new medications and precision medicine are changing diabetes care.

Dace Trence MD, FACE is the Director of the Endocrine and Diabetes Care Center at the University of Washington in Seattle.


Transcript of this video segment, Dace Trence Part 5, Diabetes and Cardiovascular Combo Therapy:

Freed: Give me one of the biggest changes, especially for endocrinologists who are specialists in the treatment of diabetes. Is that — was, it was always about blood sugars? That we never had any drugs to treat cardiovascular situations. And all of a sudden now–

Trence: Well, we did separately.

Freed: Right.

Trence: And we did separately, so we attended to blood pressure, lipids, the aspirin, the plavix, things like that.

Freed: But now, because we have these drugs that do both–

Trence: Yes.

Freed: –how has that changed the way you treat patients?

Trence: I think, first of all, it’s made it easier to get some of these drugs because insurances are recognizing that they have additional value beyond just glucose lowering. That’s been a big change because they’re still expensive, but the door is a little bit more open in terms of who can get these. So, it isn’t quite, “Nope, the FDA approves it for this and that’s all we’re going to do.” Of course FDA now has also been a little bit more liberal too in their additional benefits and indications. But I think it’s added some additional thought processes to in this particular person, “What might be the best regimen to help control the blood sugar?” So, it’s a different layer than just looking at blood sugar and it goes beyond cardiovascular. There’s also the renal benefits we’re seeing from of these drugs. So, they’re additional benefits that you can actually begin to tailor a regiment towards a particular person. It’s moving in the air of what many people are calling precision medicine. So, it’s not just calling, “Okay. Step one, you do this. Step three, you do this. Step five, you do this type of thing.” It’s really, “Okay. I have this individual in front of me. What medication regimens can I really prescribe or suggest to this person that really have the most benefit?”

Freed: Well, I don’t want to take any more of your time. I really appreciate you coming down here.

Trence: Thank you.

Freed: Enjoy the rest of your stay here in Boston. And like everybody else, we’ll be looking forward to ADA and some exciting results coming out of some of these studies. Well, thanks again!

Trence: Thank you!

Return to the main page.